Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046477 | 0.74 | ALDH1A1 (0.46) | ALDH1A1MAPTHTTGAAMAP1LC3B | |
| SCHEMBL14889997 | 0.71 | MEN1 (0.63) | ALDH1A1MAPTHTTGAAMEN1 | |
| SCHEMBL10046482 | 0.69 | GAA (0.51) | ALDH1A1MAPTHTTGAAMEN1 | |
| SCHEMBL10046491 | 0.69 | TSHR (0.41) | ALDH1A1MAPTHTTGAAMEN1 | |
| SCHEMBL3004220 | 0.64 | ALDH1A1 (0.43) | ALDH1A1MAPTHTTGAAMAP1LC3B | |
| SCHEMBL3129599 | 0.64 | ALDH1A1 (0.72) | ALDH1A1MAPTHTTGAAMEN1 | |
| SCHEMBL2996159 | 0.64 | ALDH1A1 (0.45) | ALDH1A1MAPTHTTGAAMAP1LC3B | |
| SCHEMBL3119482 | 0.63 | ALDH1A1 (0.71) | ALDH1A1MAPTHTTGAAMEN1 | |
| SCHEMBL3005893 | 0.63 | ALDH1A1 (0.42) | ALDH1A1MAPTHTTGAAMAP1LC3B | |
| SCHEMBL2991219 | 0.63 | ALDH1A1 (0.42) | ALDH1A1MAPTHTTGAAMAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906416-B2 | Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2014-12-09 | — | — | US | disclosed |
| EP-2590959-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | Pierre Fabre Dermo-Cosmétique (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004390-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130108568-A1 | XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS | ACOX3, CBR3, GALR3 | ALDH1A1 1099/4885MAPT 3426/4885HTT 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.